WSJ
04 Sept 2026, 21:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
A Phase 3 study showed the company's drug failed to reduce the risk of cardiovascular events. — Phase 3 failure typically eliminates the primary path to regulatory approval and commercialization for a key product candidate.
-0.90The company's shares declined in after-hours trading following the study results. — Immediate price action confirms negative market sentiment and the discounting of the drug's future cash flows.
-0.30Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Continue reading
6 related stories
Top 1 mover · tap to explore
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
7h ago
